keyword
MENU ▼
Read by QxMD icon Read
search

cetuximab head and neck cancers

keyword
https://www.readbyqxmd.com/read/29650896/-the-combination-of-molecular-targeted-agents-with-radiotherapy-in-head-and-neck-cancer
#1
Mitsuhiro Furuta, Tomoya Yokota
Concurrent cisplatin based chemoradiotherapy(CRT)is the standard of care for patients with locoregionally advanced squamous cell carcinoma of the head and neck(LA-SCCHN). Based on the Bonner trial showing the superiority of cetuximab plus radiotherapy to radiotherapy alone, cetuximab based bioradiotherapy(BRT)is considered as an alternative for patients with LA-SCCHN. However, the non-inferiority of BRT compared to CRT has not yet been demonstrated. Furthermore, severe mucositis and dermatitis induced by BRT cannot be neglected...
March 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29604587/apigenin-enhances-the-antitumor-effects-of-cetuximab-in-nasopharyngeal-carcinoma-by-inhibiting-egfr-signaling
#2
Wen-Jian Hu, Jing Liu, Lun-Kun Zhong, Jian Wang
Nasopharyngeal carcinoma (NPC) is a type of head and neck cancers with poor prognosis. Despite that platinum-based chemotherapy concurrent with radiotherapy have made great achievements for the treatment of NPC, the therapeutic reaction and toxicity varies dramatically among individuals. Apigenin (API), a naturally occurring plant flavone, is considered to have anti-cancer effect. Cetuximab (CET), a well known epidermal growth factor receptor (EGFR) inhibitor, is widely used in various cancers, especially head and neck cancers...
March 28, 2018: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/29568372/effects-of-cetuximab-and-erlotinib-on-the-behaviour-of-cancer-stem-cells-in-head-and-neck-squamous-cell-carcinoma
#3
Maria Fernanda Setúbal Destro Rodrigues, Luke Gammon, Muhammad M Rahman, Adrian Biddle, Fabio Daumas Nunes, Ian C Mackenzie
The therapeutic responses of many solid tumours to chemo- and radio-therapies are far from fully effective but therapies targeting malignancy-related cellular changes show promise for further control. In head and neck squamous cell carcinoma, the epidermal growth factor receptor (EGFR) is commonly overexpressed and investigation of agents that block this receptor indicate a limited response when used alone but an ability to enhance the actions of other drugs. The hierarchical stem cell patterns present in tumours generate cellular heterogeneity and this is further complicated by cancer stem cells (CSC) shifting between epithelial (Epi-CSC) and mesenchymal (EMT-CSC) states...
March 2, 2018: Oncotarget
https://www.readbyqxmd.com/read/29556677/a-feasibility-study-on-adaptive-18-f-fdg-pet-guided-radiotherapy-for-recurrent-and-second-primary-head-and-neck-cancer-in-the-previously-irradiated-territory
#4
Julie Schatteman, Dirk Van Gestel, Dieter Berwouts, Werner De Gersem, Geert De Kerf, Wilfried De Neve, Bie De Ost, Ana Maria Luiza Olteanu, Sylvie Rottey, Tom Vercauteren, Ingeborg Goethals, Fréderic Duprez
PURPOSE: To evaluate feasibility, disease control, survival, and toxicity after adaptive 18 F-fluorodeoxyglucose (FDG) positron emisson tomography (PET) guided radiotherapy in patients with recurrent and second primary head and neck squamous cell carcinoma. METHODS: A prospective trial investigated the feasibility of adaptive intensity modulated radiotherapy (IMRT) ± concomitant cetuximab in 10 patients. The primary endpoint was achieving a 2-year survival free of grade >3 toxicity in ≥30% of patients...
March 19, 2018: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/29552307/characterization-of-7a7-an-anti-mouse-egfr-monoclonal-antibody-proposed-to-be-the-mouse-equivalent-of-cetuximab
#5
Xuzhi He, Jazmina L Cruz, Shannon Joseph, Nicola Pett, Hui Yi Chew, Zewen K Tuong, Satomi Okano, Gabrielle Kelly, Margaret Veitch, Fiona Simpson, James W Wells
The Epidermal Growth Factor Receptor (EGFR) is selectively expressed on the surface of numerous tumours, such as non-small cell lung, ovarian, colorectal and head and neck carcinomas. EGFR has therefore become a target for cancer therapy. Cetuximab is a chimeric human/mouse monoclonal antibody (mAb) that binds to EGFR, where it both inhibits signaling and induces cell death by antibody-dependent cell mediated cytotoxicity (ADCC). Cetuximab has been approved for clinical use in patients with head and neck squamous cell carcinoma (HNSCC) and colorectal cancer...
February 23, 2018: Oncotarget
https://www.readbyqxmd.com/read/29541413/combined-modality-radiation-therapy-promotes-tolerogenic-myeloid-cell-populations-and-stat3-related-gene-expression-in-head-and-neck-cancer-patients
#6
Sagus Sampath, Haejung Won, Erminia Massarelli, Min Li, Paul Frankel, Nayana Vora, Lalit Vora, Ellie Maghami, Marcin Kortylewski
Immunomodulation contributes to the antitumor efficacy of the fractionated radiation therapy (RT). Here, we describe immune effects of RT with concurrent systemic cisplatin or cetuximab treatment of patients with stage III-IV head and neck squamous cell carcinoma (HNSCC). Using longitudinally collected blood samples, we identified significant changes in cytokines/chemokines and immune cell populations compared to immune-related gene expression profiles in peripheral blood mononuclear cells (PBMCs). The 7-week combinatorial RT resulted in gradual elevation of proinflammatory mediators (IFNγ, IL-6, TNFɑ, CCL2), while levels of IL-12, cytokine essential for antitumor immune responses, were decreased...
February 16, 2018: Oncotarget
https://www.readbyqxmd.com/read/29540490/stat3-hotair-signaling-axis-regulates-hnscc-growth-in-an-ezh2-dependent-manner
#7
Shanshan Sun, Yansheng Wu, Wenyu Guo, Feng Yu, Lingping Kong, Yu Ren, Yu Wang, Xiaofeng Yao, Chao Jing, Chao Zhang, Mingyang Liu, Yuqing Zhang, Minghui Zhao, Zhaoqing Li, Chuanqiang Wu, Yu Qiao, Jingxuan Yang, Xudong Wang, Lun Zhang, Min Li, Xuan Zhou
PURPOSE: Phosphotidylinositol-3-kinase (PI3K)and signal transducers and activators of transcription 3 (STAT3) are frequently activated in cancer progression. However, little is known about the underlying mechanisms by which PI3K and STAT3 regulate HNSCC growth. The lncRNA HOX transcript antisense RNA (HOTAIR) was found to modulate the progression of head and neck squamous cell cancer (HNSCC). In this study, we attempted to establish the correlation of PI3K-STAT3-HOTAIR signaling with the progression of HNSCC and its sensitivity towards platinum-based and targeted anti-EGFR combination therapy...
March 14, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29537684/cost-effectiveness-analysis-of-salvage-therapies-in-locoregional-previously-irradiated-head-and-neck-cancer
#8
HaYeon Kim, John A Vargo, Sushil Beriwal, David A Clump, James P Ohr, Robert L Ferris, Dwight E Heron, M Saiful Huq, Kenneth J Smith
BACKGROUND: The purpose of this study was to present our evaluation of the cost-effectiveness of salvage therapies for patients with recurrent head and neck cancer. METHODS: A Markov model was developed with 5 salvage treatment strategies: (1) platinum-based chemotherapy alone; (2) chemotherapy plus cetuximab; (3) stereotactic body radiotherapy (SBRT) alone; (4) SBRT plus cetuximab; and (5) intensity-modulated radiotherapy (IMRT) plus chemotherapy. Clinical parameters were obtained from comprehensive literature review and 2016 Medicare reimbursement...
March 14, 2018: Head & Neck
https://www.readbyqxmd.com/read/29534625/cetuximab-for-treating-non-small-cell-lung-cancer
#9
Luca Mazzarella, Alessandro Guida, Giuseppe Curigliano
Epidermal Growth Factor Receptor (EGFR)-dependent signaling plays a crucial role in epithelial cancer biology, and dictated the development of several targeting agents. The mouse-human chimeric antibody Cetuximab was among the first to be developed. After about two decades of clinical research it has gained a significant place in the management of advanced colorectal and head and neck cancers, whereas its development in non small cell lung cancer (NSCLC) has not led to a place in routine clinical practice, because of marginal clinical benefit despite statistically significant Phase III trials...
March 14, 2018: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29530457/patient-characteristics-and-costs-in-recurrent-or-refractory-head-and-neck-cancer-retrospective-analysis-of-a-community-oncology-database
#10
Maxine D Fisher, Ancilla W Fernandes, Temitope O Olufade, Paul J Miller, Mark S Walker, Moon Fenton
PURPOSE: The goal of this study was to describe patient characteristics, health resource utilization (HRU), and costs associated with treating recurrent or refractory head and neck cancer (HNC) among patients with disease progression in the community oncology setting. METHODS: This retrospective observational study was conducted by using data from the Vector Oncology Data Warehouse. Patients had been diagnosed with locally advanced or metastatic (stage III-IVc) HNC between January 1, 2007, and October 1, 2015...
March 9, 2018: Clinical Therapeutics
https://www.readbyqxmd.com/read/29496049/sting-activation-enhances-cetuximab-mediated-nk-cell-activation-and-dc-maturation-and-correlates-with-hpv-status-in-head-and-neck-cancer
#11
Shanhong Lu, Fernando Concha-Benavente, Gulidanna Shayan, Raghvendra M Srivastava, Sandra P Gibson, Lin Wang, William E Gooding, Robert L Ferris
OBJECTIVES: The intracellular DNA sensor stimulator of interferon genes (STING) has recently been shown to play a vital role in anti-viral and anti-tumor immune responses stimulating cytokine production. While human papillomavirus (HPV) is a causative agent for a subset of head and neck squamous cell carcinoma (HNSCC) with unique etiology and clinical outcome, how the STING pathway is regulated in a virus-induced tumor microenvironment is not well understood. Since STING inactivation likely reflects immunoescape via innate immunity, we hypothesized that its restoration would improve efficacy of the immune modulatory monoclonal antibody (mAb), cetuximab...
March 2018: Oral Oncology
https://www.readbyqxmd.com/read/29496036/combination-of-post-operative-radiotherapy-and-cetuximab-for-high-risk-cutaneous-squamous-cell-cancer-of-the-head-and-neck-a-propensity-score-analysis
#12
Joshua D Palmer, Charles J Schneider, Neil Hockstein, Alexandra L Hanlon, Jordan Silberg, Jon Strasser, Elizabeth A Mauer, Michael Dzeda, Robert Witt, Adam Raben
OBJECTIVES: The objective of this study was to investigate the safety, tolerability and preliminary efficacy of radiotherapy plus cetuximab in high risk CSCC patients. MATERIALS AND METHODS: Patients with high-risk CSCC diagnosed between 2006 and 2013 were analyzed. Patients were divided into two groups: radiotherapy alone versus radiotherapy plus cetuximab. Among 68 patients meeting study criteria, we identified 29 treated with cetuximab plus RT and 39 with RT alone...
March 2018: Oral Oncology
https://www.readbyqxmd.com/read/29493423/immune-cell-infiltration-in-head-and-neck-squamous-cell-carcinoma-and-patient-outcome-a-retrospective-study
#13
Karolin Schneider, Etienne Marbaix, Caroline Bouzin, Marc Hamoir, Pierre Mahy, Vanesa Bol, Vincent Grégoire
BACKGROUND: Human papillomavirus (HPV) prevalence in oropharynx squamous cell carcinoma (OPSCC) is on the rise. HPV-linked OPSCCs represent a distinct clinical entity with a better treatment response and patient survival compared to tumors not linked to HPV. An emerging role in treatment response has been attributed to immune cell infiltration in human tumors. In this study, we investigated immune cell infiltration in human SCC of the head and neck region and its relation to overall survival after treatment with surgery (with or without radiotherapy) or concomitant chemo (or cetuximab)-radiotherapy...
March 1, 2018: Acta Oncologica
https://www.readbyqxmd.com/read/29466887/access-to-anti-cancer-drugs-in-india-is-there-a-need-to-revise-reimbursement-policies
#14
Gertruud Haitsma, Himanshu Patel, Parthasarathi Gurumurthy, Maarten J Postma
BACKGROUND: The aim of this study was to examine the access of Indian cancer patients to optimum cancer care under selected government schemes by reviewing reimbursement schemes for cancer care in India. METHODS: All cancer care reimbursement schemes in India were identified and three highly utilized schemes (VAS, RAS, CMCHS) were selected. Quality of breast, colorectal, lung, head & neck, and gastric cancer care was reviewed with respect to NCCN guidelines...
February 26, 2018: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/29464112/phase-i-study-of-tomuzotuximab-a-glycoengineered-therapeutic-antibody-against-the-epidermal-growth-factor-receptor-in-patients-with-advanced-carcinomas
#15
Walter Fiedler, Sara Cresta, Henning Schulze-Bergkamen, Sara De Dosso, Jens Weidmann, Anna Tessari, Hans Baumeister, Antje Danielczyk, Bruno Dietrich, Steffen Goletz, Alfredo Zurlo, Marc Salzberg, Cristiana Sessa, Luca Gianni
Background: Changes in glycosylation of the constant domain (Fc) of monoclonal antibodies (mAbs) enhance antibody-dependent cell-mediated cytotoxicity independently of downstream effects following receptor blockade by the antibody, thus extending their indication. We investigated the safety, pharmacokinetics, pharmacodynamics and antitumour activity of tomuzotuximab, an IgG1 glycoengineered mAb against the epidermal growth factor receptor with enhanced tumour cytotoxicity in a phase I dose-escalation study (NTC01222637)...
2018: ESMO Open
https://www.readbyqxmd.com/read/29441454/chemotherapy-and-immunotherapy-for-recurrent-and-metastatic-head-and-neck-cancer-a-systematic-review
#16
REVIEW
Alessandro Guidi, Carla Codecà, Daris Ferrari
Head and neck cancer (HNC) is a fatal malignancy with an overall long-term survival of about 50% for all stages. The diagnosis is not rarely delayed, and the majority of patients present with loco-regionally advanced disease. The rate of second primary tumors after a diagnosis of HNC is about 3-7% per year, the highest rate among solid tumors. Currently, a single-modality or a combination of surgery, radiotherapy and chemotherapy (CHT), is the standard treatment for stage III-IV HNC. For the recurrent/metastatic setting, in the last 40 years great efforts have been made in order to develop a more effective CHT regimen, from the use of methotrexate alone, to the combination of cisplatin (CDDP) and 5-fluorouracile (5FU) or paclitaxel...
February 13, 2018: Medical Oncology
https://www.readbyqxmd.com/read/29435842/perspectives-in-head-and-neck-medical-oncology
#17
Idoroenyi Amanam, Rohan Gupta, Alain Mita, Kevin Scher, Erminia Massarelli
The modern treatment of locoregionally advanced disease often requires a multimodality combination approach. A number of chemotherapeutic agents can be combined with radiation, but the platinum agent cisplatin, a potent radiation sensitizer, is best studied in head and neck cancer. Newer agents such as cetuximab can be used in combination with radiation therapy for those patients who cannot tolerate cisplatin. For chemotherapy-naïve patients with metastatic head and neck cancer who demonstrate a good performance status, platinum doublet regimens are commonly used...
2018: Cancer Treatment and Research
https://www.readbyqxmd.com/read/29432222/immunotherapy-for-recurrent-metastatic-head-and-neck-cancer
#18
Salvatore Alfieri, Stefano Cavalieri, Lisa Licitra
PURPOSE OF REVIEW: In the last decade, after cetuximab (anti-epidermal growth factor receptor), none of the novel investigated compounds has demonstrated benefit in head and neck squamous cell cancers (HNSCC), both in advanced and curative settings. Therefore, prognosis of recurrent/metastatic (R/M) HNSCC patients remains dismal, especially in platinum-refractory cohort. In the last few years, a new important class of drugs has affirmed its role. HNSCC, even if less 'immunogenic' than other malignancies (e...
April 2018: Current Opinion in Otolaryngology & Head and Neck Surgery
https://www.readbyqxmd.com/read/29411154/modified-biweekly-cisplatin-docetaxel-plus-cetuximab-tpex-as-first-line-treatment-for-patients-with-recurrent-metastatic-head-and-neck-cancer
#19
Hannah Fuchs, Johannes Pammer, Christoph Minichsdorfer, Doris Posch, Gabriela Kornek, Marie-Bernadette Aretin, Thorsten Fuereder
Three weekly high-dose chemotherapy regimens in combination with weekly cetuximab are the treatment of choice for patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (SCCHN), although the majority of patients suffer from severe side effects. Thus, we investigated the efficacy and safety of an alternative, more convenient and less toxic biweekly modified cisplatin, docetaxel plus cetuximab (TPEx) regimen in this retrospective analysis. Thirty-eight patients receiving off-protocol cisplatin (50 mg/m2) in combination with docetaxel (50 mg/m2) plus cetuximab (500 mg/m2) every other week were included...
February 7, 2018: Medical Oncology
https://www.readbyqxmd.com/read/29398127/carotid-dosimetry-and-the-risk-of-carotid-blowout-syndrome-after-reirradiation-with-head-and-neck-stereotactic-body-radiation-therapy
#20
Brian J Gebhardt, John A Vargo, Diane Ling, Brianna Jones, Mary Mohney, David A Clump, James P Ohr, Robert L Ferris, Dwight E Heron
PURPOSE: To correlate carotid dose and risk of carotid blowout syndrome (CBOS) after stereotactic body radiation therapy (SBRT), hypothesizing that carotid dose does not correlate with CBOS. METHODS AND MATERIALS: We retrospectively reviewed 186 patients with recurrent, previously irradiated head and neck cancer treated between January 2008 and March 2013. Patients treated early in our experience with incomplete dosimetry were excluded from analysis (n = 111). A total of 75 patients were identified, providing 150 carotid arteries for analysis...
December 5, 2017: International Journal of Radiation Oncology, Biology, Physics
keyword
keyword
54952
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"